MARKET

BMRN

BMRN

Biomarin Pharmaceutical Inc
NASDAQ
77.05
-0.51
-0.66%
After Hours: 77.05 0 0.00% 17:38 05/20 EDT
OPEN
77.52
PREV CLOSE
77.56
HIGH
77.58
LOW
76.25
VOLUME
1.73M
TURNOVER
0
52 WEEK HIGH
99.56
52 WEEK LOW
76.02
MARKET CAP
14.63B
P/E (TTM)
72.93
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BMRN last week (0513-0517)?
Weekly Report · 1d ago
Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)
NICE Ltd shares tumbled after the company reported Q1 financial results and issued Q2 adjusted revenue guidance below estimates. Petroleo Brasileiro shares plummeted after Q1 sales missed consensus. Comfort Systems USA, Inc. Stock fell in the last week. These 10 large-cap stocks were the worst performers.
Benzinga · 1d ago
4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Despite the Nasdaq Composite climbing to a new all-time high, plain-as-day bargains can still be found in growth stocks. The Nasdaq is in a bull market and the growth-focused Nasdaq composite has rallied 60%. Four growth stocks you might regret not buying in the new Nasdaq bull market. Social media leader Meta Platforms and online-services marketplace Fiverr International are among them.
The Motley Fool · 3d ago
Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
Piper Sandler cut the price target for Globant from $290 to $238. Morgan Stanley cut Weibo Corporation's price target from $11 to $10. Baird slashed the price targets for BioMarin Pharmaceutical Inc. And Take-Two Interactive Software. Walmart Inc. Shares rose 7% on Thursday.
Benzinga · 4d ago
BioMarin Pharmaceutical Price Target Cut to $72.00/Share From $104.00 by Baird
Dow Jones · 4d ago
BioMarin Pharmaceutical Cut to Neutral From Outperform by Baird
Dow Jones · 4d ago
Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS)
TipRanks · 4d ago
Baird Downgrades Biomarin Pharmaceutical to Neutral, Lowers Price Target to $72
Benzinga · 4d ago
More
About BMRN
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Webull offers Biomarin Pharmaceutical Inc stock information, including NASDAQ: BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.